Capital International Investors 13F: Cuts DHR Stake by $822M
The fund trimmed its Danaher holdings, now holding 14 million shares valued at $2.75 billion.
Reviewed by automated data checks against the source filing. How we make and check alerts
Capital International Investors sold 4,231,295 shares from its stake in Danaher Corporation ($DHR), a 23.19% decrease, according to a 13F filing with the SEC dated May 13, 2026. It reported 14,014,713 shares worth $2.72 billion at the end of the quarter.
Since the filing, $DHR is up 3.1% after 1 week, up 8.5% after 1 month and up 38.5% to date (from the $165.35 close on May 13, 2026).
Find the original: Capital International Investors 13F filings on SEC EDGAR
DHR
Danaher Corporation
Key Points
- Capital International Investors cut its stake in Danaher Corporation by 23.2%, reducing its holdings by about 4.2 million shares.
- Capital International Investors held 14,014,713 $DHR shares at quarter end, down 23.19% from the prior quarter.
- Danaher's stock traded near $196.05 on Friday, with a market cap of $136.7 billion and a P/E ratio of 37.4.
- Insider buying was observed with multiple purchases, and analysts have set varied price targets, with a consensus recommendation of 'strong buy'.
Get $DHR trade alerts by text
We text you when insiders, Congress or big funds trade $DHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Capital International Investors has reduced its stake in Danaher Corporation (NYSE: DHR) by 23.2%, according to its latest Form 13F filing with the SEC. The fund sold 4,231,295 shares, leaving it with 14,014,713 shares valued at approximately $2.75 billion. This filing reflects their holdings as of the reporting period and may not represent their current position.
Capital International Investors vs. the S&P 500
Hypothetical returns from Capital International Investors's disclosed trades, not real profit or advice. How we model this.
What Changed in Capital International Investors' Danaher Position
Capital International Investors cut its holdings in Danaher from 18,246,008 shares to 14,014,713 shares, a decrease of 23.2%. The shares are now valued at about $2.75 billion, down from their previous value. This significant reduction shows a strategic shift in the fund's portfolio.
Other Institutional Activity in Danaher
Other major institutional investors have also made moves in Danaher. BlackRock, Inc. slightly reduced its position by 396,733 shares, ending with 51,640,619 shares valued at $9.79 billion. Vanguard Capital Management LLC opened a new position with 41,127,810 shares worth approximately $7.80 billion. State Street Corp increased its holdings by 212,847 shares to a total of 27,894,181 shares, valued at $5.30 billion. Meanwhile, FMR LLC added 3,027,600 shares, bringing its total to 22,534,329 shares, worth about $4.27 billion. JPMorgan Chase & Co reduced its stake significantly by 4,667,877 shares, leaving it with 16,917,649 shares valued at $3.11 billion.
Danaher Corporation Stock Down 13.6%
Shares of NYSE:DHR traded near $196.05 on Friday. Danaher Corporation boasts a market cap of $136.7 billion and a P/E ratio of 37.4. The stock's 52-week range has been between $160.93 and $242.80. It currently has a 50-day moving average of $178.79 and a 200-day moving average of $203.93. The company maintains a current ratio of 1.87 and a quick ratio of 1.40, with a debt-to-equity ratio of 37.17.
Recent Earnings
Danaher's recent earnings report showed revenue of $24.78 billion, with a growth rate of 3.7%. The company's earnings per share stood at $5.16, with a net margin of 14.9% and a return on equity of 7.1%. The next earnings report is scheduled for July 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60, yielding 0.83% with a payout ratio of 26.36%. The ex-dividend date has not been specified.
Insider Buying and Selling at Danaher Corporation
Recent insider activity at Danaher includes several purchases on May 15, 2026. Charles Lamanna, Shane Sanders, Linda Filler, and Alan Spoon each bought 1,699 shares, while Sanders and Filler also purchased an additional 680 shares each. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 11, 2026, Piper Sandler initiated coverage of Danaher with a 'hold' rating and a $200 price target. HSBC maintained a 'buy' rating with a $230 target on June 3, 2026. Citigroup reinstated its 'buy' rating with a $230 target on May 27, 2026, while also downgrading it to 'hold' with a $95 target on the same day. RBC Capital reinstated a 'buy' rating with a $200 target on May 15, 2026. The consensus among 23 analysts is a 'strong buy' with a mean target price of $242.35.
About Danaher Corporation
Danaher Corporation, headquartered in Washington, DC, designs and markets professional, medical, and industrial products globally. The company operates in the Biotechnology, Life Sciences, and Diagnostics segments, offering a range of technologies and services for therapeutics development, lab solutions, and diagnostic tools. Led by CEO Rainer M. Blair, Danaher employs around 58,000 people worldwide.
Bottom Line
Capital International Investors' decision to cut its stake in Danaher Corporation highlights shifting strategies among institutional investors. Danaher's stock remains a focus due to its significant market presence in the healthcare sector. Investors will be watching closely for any further changes in holdings and analyst ratings as the next earnings report approaches. Remember, 13F filings are backward-looking and may not reflect the current position of the fund.
Related Filing Alerts
Source: Capital International Investors's 13F filing on $DHR (May 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Capital International Investors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts